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OBJECTIVES: To assess the relationship between quality of life
and willingness to pay of asthma patients classiﬁed with disease
severity and age in Korea. METHODS: A total of 549 Patients
diagnosed asthma were recruited for this study enrollment with
the support of Korean Asthma Allergy Foundation in April 2004.
Patients are composed to Adults, children with asthma and the
children’s care giver. Severity of disease was assessed a patient’s
FEV1 based on the patients’ medical record and classiﬁed by four
groups. National approved disease speciﬁc questionnaires for
adults and the care givers measured patient’s quality of life. To
measure willingness to pay for treatment of asthma, 3 methods,
binary contingent valuation question, open-ended question and
bidding game were used in this study. RESULTS: WTP has
a trend of increasing in more severe patients, especially in
the group of caregiver of children with asthma. Also, QOL
was related to severity of asthma very much in signiﬁcantly
(p < 0.001). QOL score of adult with asthma was better than
that of the caregiver. The adjusted average WTP of the care giver
($244/year) was higher than that of adult ($174/year) for every
patient. The yearly average WTP of adult was $139 and $210 for
mild and severe asthma, respectively, while that of the care giver
was $187 and $302 for mild and severe asthma, respectively.
CONCLUSION: Both WTP and QOL were highly related to
severity of disease. From the ﬁndings in this study, the caregiver
of children with asthma felt that the disease sometimes make
their lives more difﬁcult and have higher willingness to pay for
treatment their children’s disease than adult patients.
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OBJECTIVES: UK General Medical Services Quality Outcomes
Framework (QOF) set 5 mmol/L total cholesterol (TC) as an
audit standard for diabetes. European and British expert guide-
lines recommend lower total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C) targets. This observational study
reviewed rosuvastatin in UK general practice. METHODS:
Surveys of rosuvastatin 10 mg (R10) in routine general practice
were provided as a medical service by AstraZeneca from 2004.
Permission to analyse anonymised data was granted by
101/150 practices that participated before 2006. Analyses of
patients with diabetes achieving TC QOF target 5 mmol/L,
Joint European Societies (JES) targets TC < 4.5 mmol/L and
LDL-C < 2.5 mmol/L, and Joint British Society (JBS2) Targets
TC < 4 mmol/L and <2 mmol/L, pre and on R10 were con-
ducted. RESULTS: TC test results were available prior to and on
R10 for 2868 patients on practice diabetes registers (1726
patients statin naïve, 1142 switched from another statin). Statins
commonly prescribed were simvastatin and atorvastatin. When
comparing results prior to and on R10 the following were
observed: TC reduction -‘all’ (28%) ‘new’ (32%) ‘switch’ (19%)
groups (p < 0.001); LDL-C reduction—‘all’ (39%) ‘new’ (45%)
‘switch’ (28%) groups (p < 0.001). A greater proportion on
R10 compared to prior treatment achieved: QOF target TC
5 mmol/L—‘all’ (24%: 85%), ‘new’ (14%: 86%), ‘switch’
groups (38%: 83%) (all p < 0.0001); JES target TC 4.5 mmol/
L—‘all’ (15%: 71%), ‘new’ (8%: 46%), ‘switch’ (26%: 65%
groups and LDL-C goal <2.5 mmol/L—‘all’ (24%: 79%), ‘new’
(12%: 80%), ‘switch’ (41%: 78%) groups (p < 0.0001);
JBS2 goal TC < 4 mmol/L—‘all’ (7%: 51%), ‘new’ (4%: 56%),
‘switch’ (13%: 43%) groups and LDL-C goal <2 mmol/L—‘all’
(11%: 59%), ‘new’ (5%: 61%), ‘switch’ (19%: 55%) groups
(p < 0.0001). CONCLUSION: Use of rosuvastatin 10 mg in
general practice across UK helped greater proportions of patients
with diabetes reach QOF, European and British targets.
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OBJECTIVES: Guidelines (JNC VII; ESH-ESC) recommend
treatment with two or more antihypertensives to reach BP goals.
This study examined the “real-world” effectiveness on BP
outcomes for newly diagnosed hypertensives treated with
triple-therapy (valsartan-amlodipine-HCTZ) as compared to
mono-therapy (amlodipine). METHODS: A retrospective review
of an ambulatory electronic medical record (EMR) database of
US patients was conducted. Hypertensive adults were identiﬁed
on the medications of interest. Newly diagnosed hypertensive
had no diagnosis for hypertension or antihypertensive medica-
tions in the 13 months prior to the index date (ﬁrst mention of
the medications of interest). Baseline BP reading was obtained
within 14 days of the medication start date and a post-BP >30
days but <365 days after. Mean change in BP and percentage of
patients attaining BP goal were calculated. A sub-analysis of
stage 1 and 2 hypertensives was also conducted. RESULTS:
There were 72 mono-therapy and 249 triple-therapy patients
identiﬁed. Baseline demographics were similar (mean age, gender,
comorbid diabetes). No statistical difference was observed in
baseline BPs (mono-therapy 156/86; triple-therapy 154/85).
Triple-therapy patients experienced statistically signiﬁcant higher
levels of BP goal attainment (49.5% for triple-therapy; 27.6%
for mono-therapy) and statistically signiﬁcant greater reductions
in BPs. Mono-therapy patients achieved modest reductions in
SBP [5 mmHg (95% CI: -0.84, 10.84) and DBP [4 mmHg (95%
CI: 0.85, 7.15)]. Triple-therapy patients experienced greater
reductions in SBP [16 mmHg (95% CI: 12.53, 19.47)] and DBP
[7 mmHg (95% CI: 5.14, 8.86)]. The BP reductions with triple-
therapy were even greater in stage 2 hypertensives. [N = 109; SBP
33 mmHg (95% CI: 27.94, 38.06); DBP 14 mmHg (95% CI:
11.04, 16.96)]. CONCLUSION: Current guidelines recommend
combining hypertensive medications with different mechanisms
of action to achieve BP control. Utilizing an EMR database of
predominantly primary care patients, this study demonstrates the
“real-world” effectiveness of triple-therapy with valsartan, amlo-
dipine and HCTZ.
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